|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3800 AUD | +1.33% |
|
+1.33% | -41.54% |
| 07-30 | Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy | MT |
| 07-21 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| Market Cap | 112M 79.22M 68.62M 63.96M 58.83M 111M 7.53B 752M 295M 3.77B 298M 291M 12.48B | P/E 2026 * |
-6.15x | P/E 2027 * | -4.41x |
|---|---|---|---|---|---|
| Enterprise Value | 118M 82.92M 71.81M 66.94M 61.57M 116M 7.88B 787M 309M 3.94B 311M 305M 13.07B | EV / Sales 2026 * |
15.1x | EV / Sales 2027 * | 11x |
| Free-Float |
62.7% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +1.33% | ||
| 1 week | +1.33% | ||
| Current month | +2.70% | ||
| 3 months | -20.83% | ||
| 6 months | -33.33% | ||
| Current year | -41.54% |
| 1 week | 0.36 |  | 0.38 |
| 1 month | 0.35 | | 0.39 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.76 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/02/26 | Expiration | Chief Executive Officer | 2,250,000 | 0.7781% | ||
| 14/10/25 | Expiration | Chief Executive Officer | 745,962 | 0.3217% | ||
| 21/11/24 | Buy | Director | 1,000,000 | 0.4313% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +1.33% | +2.70% | -37.70% | 79.22M | |
| +4.86% | -3.32% | +52.73% | +160.26% | 1,043B | |
| +1.04% | -2.99% | +50.87% | +52.38% | 621B | |
| +0.98% | -6.49% | +24.00% | +66.66% | 435B | |
| +0.85% | +4.36% | +48.35% | +39.25% | 361B | |
| +1.05% | -0.76% | +36.21% | +40.03% | 293B | |
| +0.21% | -5.01% | +9.31% | +11.00% | 251B | |
| +4.57% | +5.21% | +35.91% | +67.64% | 220B | |
| +0.80% | -10.58% | +2.21% | -45.78% | 201B | |
| -2.58% | -0.73% | +17.16% | +67.46% | 164B | |
| Average | +0.89% | -3.16% | +27.95% | +42.12% | 358.92B | |
| Weighted average by Cap. | +0.88% | -3.79% | +38.61% | +76.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.78M 5.49M 4.75M 4.43M 4.08M 7.69M 522M 52.07M 20.44M 261M 20.61M 20.16M 865M | 12.5M 8.82M 7.63M 7.12M 6.55M 12.36M 838M 83.63M 32.83M 419M 33.11M 32.38M 1.39B |
| Net income | -18.29M -12.9M -11.18M -10.42M -9.58M -18.09M -1.23B -122M -48.05M -614M -48.47M -47.4M -2.03B | -25.1M -17.71M -15.34M -14.3M -13.15M -24.82M -1.68B -168M -65.93M -842M -66.5M -65.03M -2.79B |
| Net Debt | 5.24M 3.69M 3.2M 2.98M 2.74M 5.18M 351M 35.04M 13.75M 176M 13.87M 13.56M 582M | 24.96M 17.61M 15.25M 14.22M 13.08M 24.69M 1.67B 167M 65.58M 838M 66.14M 64.68M 2.77B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/08/26 | A$0.3800 | +1.33% | 45,217 |
| 05/08/26 | A$0.3750 | 0.00% | 7,916 |
| 04/08/26 | A$0.3750 | -1.32% | 6,060 |
| 03/08/26 | A$0.3800 | +2.70% | 120,803 |
| 31/07/26 | A$0.3700 | -1.33% | 29,912 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
